# Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

> **NCT00688545** · — · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 275 (actual)

## Conditions studied

- Arthritis, Juvenile Rheumatoid

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** nsNSAIDs

## Key facts

- **NCT ID:** NCT00688545
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 275 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00688545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00688545, "Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00688545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*